



## Clinical trial results: A Phase I Study of Ridaforolimus in Paediatric Patients with Advanced Solid Tumours

### Summary

EudraCT number	2011-000729-55
Trial protocol	GB FR Outside EU/EEA
Global end of trial date	25 May 2018

### Results information

Result version number	v3 (current)
This version publication date	15 November 2018
First version publication date	19 July 2015
Version creation reason	

### Trial information

#### Trial identification

Sponsor protocol code	8669-056
-----------------------	----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01431534
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill RD, Kenilworth NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000458-PIP01-08
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 April 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 August 2013
Global end of trial reached?	Yes
Global end of trial date	25 May 2018
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objectives of this trial are to determine the recommended dose of ridaforolimus for pediatric participants with advanced solid tumors by measuring the number of participants experiencing dose-limiting toxicities (DLTs) while on different doses of ridaforolimus, and to characterize the pharmacokinetics of ridaforolimus in these participants.

Study-related visits concluded in August 2013. Participants who did not have disease progression, adequately tolerated therapy, and continued to meet eligibility criteria for 6 months after the enrollment period had been completed could continue treatment in an extension phase until they met discontinuation criteria or voluntarily withdrew.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 January 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	United States: 4
Worldwide total number of subjects	20
EEA total number of subjects	16

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	7
Adolescents (12-17 years)	13
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study enrolled children from the ages of 6 to <18 years with advanced solid tumors including lymphoma and tumors of the central nervous system who met the study inclusion/exclusion criteria

### Period 1

Period 1 title	Treatment Phase
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Ridaforolimus 22 mg/m <sup>2</sup>

Arm description:

Participants received 22 mg/m<sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.

Arm type	Experimental
Investigational medicinal product name	Ridaforolimus
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m<sup>2</sup>, 28 mg/m<sup>2</sup>, or 33 mg/m<sup>2</sup> based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.

<b>Arm title</b>	Ridaforolimus 28mg/m <sup>2</sup>
------------------	-----------------------------------

Arm description:

Participants received 28 mg/m<sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.

Arm type	Experimental
Investigational medicinal product name	Ridaforolimus
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m<sup>2</sup>, 28 mg/m<sup>2</sup>, or 33 mg/m<sup>2</sup> based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.

<b>Arm title</b>	Ridaforolimus 33 mg/m <sup>2</sup>
------------------	------------------------------------

Arm description:

Participants received 33 mg/m<sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ridaforolimus
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m<sup>2</sup>, 28 mg/m<sup>2</sup>, or 33 mg/m<sup>2</sup> based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.

<b>Number of subjects in period 1</b>	Ridaforolimus 22 mg/m <sup>2</sup>	Ridaforolimus 28mg/m <sup>2</sup>	Ridaforolimus 33 mg/m <sup>2</sup>
Started	4	3	13
Completed	0	0	2
Not completed	4	3	11
Adverse event, non-fatal	-	-	1
Progressive Disease	4	3	10

## Period 2

Period 2 title	Extension Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Ridaforolimus 33 mg/m <sup>2</sup>
------------------	------------------------------------

Arm description:

Participants receive ridaforolimus 33 mg/m<sup>2</sup>, orally, 10 mg enteric-coated tablet QD x 5/week, in 28-day cycles; this population comprises all participants who did not have disease progression, adequately tolerated therapy, and continued to meet study eligibility criteria for 6 months after the trial's enrollment period was complete.

Arm type	Experimental
Investigational medicinal product name	Ridaforolimus
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m<sup>2</sup>, 28 mg/m<sup>2</sup>, or 33 mg/m<sup>2</sup> based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.

<b>Number of subjects in period 2</b>	Ridaforolimus 33 mg/m <sup>2</sup>
Started	2
Completed	2

## Baseline characteristics

### Reporting groups

Reporting group title	Ridaforolimus 22 mg/m <sup>2</sup>
Reporting group description: Participants received 22 mg/m <sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.	
Reporting group title	Ridaforolimus 28mg/m <sup>2</sup>
Reporting group description: Participants received 28 mg/m <sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.	
Reporting group title	Ridaforolimus 33 mg/m <sup>2</sup>
Reporting group description: Participants received 33 mg/m <sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.	

Reporting group values	Ridaforolimus 22 mg/m <sup>2</sup>	Ridaforolimus 28mg/m <sup>2</sup>	Ridaforolimus 33 mg/m <sup>2</sup>
Number of subjects	4	3	13
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	1	0	6
Adolescents (12-17 years)	3	3	7
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	13.0	14.7	12.2
standard deviation	± 3.7	± 2.5	± 3.3
Gender categorical Units: Subjects			
Female	2	2	8
Male	2	1	5

Reporting group values	Total		
Number of subjects	20		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		

Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	7		
Adolescents (12-17 years)	13		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous Units: years arithmetic mean standard deviation	-		
Gender categorical Units: Subjects			
Female	12		
Male	8		

## End points

### End points reporting groups

Reporting group title	Ridaforolimus 22 mg/m <sup>2</sup>
-----------------------	------------------------------------

Reporting group description:

Participants received 22 mg/m<sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.

Reporting group title	Ridaforolimus 28mg/m <sup>2</sup>
-----------------------	-----------------------------------

Reporting group description:

Participants received 28 mg/m<sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.

Reporting group title	Ridaforolimus 33 mg/m <sup>2</sup>
-----------------------	------------------------------------

Reporting group description:

Participants received 33 mg/m<sup>2</sup> of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants could receive additional treatment in an extension phase of the study.

Reporting group title	Ridaforolimus 33 mg/m <sup>2</sup>
-----------------------	------------------------------------

Reporting group description:

Participants receive ridaforolimus 33 mg/m<sup>2</sup>, orally, 10 mg enteric-coated tablet QD x 5/week, in 28-day cycles; this population comprises all participants who did not have disease progression, adequately tolerated therapy, and continued to meet study eligibility criteria for 6 months after the trial's enrollment period was complete.

### Primary: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0)

End point title	Number of Participants Experiencing a Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0) <sup>[1]</sup>
-----------------	---

End point description:

DLT defined using NCI-CTCAE v.4.0 as any of the following events occurring during the first 28-day cycle that were possibly, probably, or definitely study drug-related: Grade 4 neutropenia for  $\geq 5$  days; Grade 3-4 neutropenia associated with fever, antibiotics, or hospitalization for infection; Grade 4 thrombocytopenia for  $\geq 5$  days or requiring platelet transfusion;  $\geq$ Grade 3 hyperglycemia for  $\geq 5$  days despite management;  $\geq$ Grade 3 diarrhea for  $> 24$  hours despite management;  $\geq$ Grade 3 nausea or vomiting despite management; any other Grade  $\geq 3$  non-hematological toxicity persisting despite management (except alopecia, transient electrolyte abnormalities, transient Grade 3 liver function test elevations, and Grade 3 neurotoxicity for participants with baseline Grade 3 neurotoxicity); inability to complete DLT assessment period, interruption in dosing for  $> 10$  dosing days during DLT assessment period, or any delay in the initiation of the next cycle for  $> 10$  dosing days due to any related toxicity.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 (cycle = 28 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this endpoint.

<b>End point values</b>	Ridaforolimus 22 mg/m <sup>2</sup>	Ridaforolimus 28mg/m <sup>2</sup>	Ridaforolimus 33 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4 <sup>[2]</sup>	3 <sup>[3]</sup>	13 <sup>[4]</sup>	
Units: Participants	0	0	1	

Notes:

[2] - Participants who completed Cycle 1 and received >75% of drug, or who discontinued due to related DLT

[3] - Participants who completed Cycle 1 and received >75% of drug, or who discontinued due to related DLT

[4] - Participants who completed Cycle 1 and received >75% of drug, or who discontinued due to related DLT

## Statistical analyses

No statistical analyses for this end point

### Primary: Area Under the Concentration-Time Curve of Ridaforolimus From Time 0 to 24 Hours (AUC0-24 hr)

End point title	Area Under the Concentration-Time Curve of Ridaforolimus From Time 0 to 24 Hours (AUC0-24 hr) <sup>[5]</sup>
-----------------	--

End point description:

AUC is a measure of the amount of drug in the blood over time. Whole blood samples were collected pre-dose (within 5 minutes of ridaforolimus administration) and post-dose at specified time points on Day 5 of the first week of Cycle 1 to determine AUC0-24 hr.

Participants who received all 5 ridaforolimus doses in the first week of 28-day Cycle 1 were analyzed.

End point type	Primary
----------------	---------

End point timeframe:

Day 5 of Cycle 1 [28-day cycle]: pre-dose (0.0 hours) and 0.5, 1.0, 2.0, 4.0, 8.0, 24.0, and 72.0 hours after administration of ridaforolimus

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was planned for this endpoint.

<b>End point values</b>	Ridaforolimus 22 mg/m <sup>2</sup>	Ridaforolimus 28mg/m <sup>2</sup>	Ridaforolimus 33 mg/m <sup>2</sup>	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	3	11	
Units: hr*ng/mL				
geometric mean (geometric coefficient of variation)	1340 (± 31.7)	2330 (± 36.2)	2280 (± 29.8)	

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to the 17-Dec-2013 database lock (up to ~56 weeks)

Adverse event reporting additional description:

All participants who received at least one dose of study treatment on the base study. Per protocol, safety data from the extension period were not included in the study database and did not contribute to the primary safety analysis.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	16.1
--------------------	------

### Reporting groups

Reporting group title	Ridaforolimus 22 mg/m <sup>2</sup>
-----------------------	------------------------------------

Reporting group description:

Participants receive ridaforolimus 22 mg/m<sup>2</sup>, orally, 10 mg enteric-coated tablet QD x 5/week, in 28-day cycles

Reporting group title	Ridaforolimus 33 mg/m <sup>2</sup>
-----------------------	------------------------------------

Reporting group description:

Participants receive ridaforolimus 33 mg/m<sup>2</sup>, orally, 10 mg enteric-coated tablet QD x 5/week, in 28-day cycles

Reporting group title	Ridaforolimus 28mg/m <sup>2</sup>
-----------------------	-----------------------------------

Reporting group description:

Participants receive ridaforolimus 28mg/m<sup>2</sup>, orally, 10 mg enteric-coated tablet QD x 5/week, in 28-day cycles

<b>Serious adverse events</b>	Ridaforolimus 22 mg/m <sup>2</sup>	Ridaforolimus 33 mg/m <sup>2</sup>	Ridaforolimus 28mg/m <sup>2</sup>
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	7 / 13 (53.85%)	2 / 3 (66.67%)
number of deaths (all causes)	1	1	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 4 (25.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurological symptom			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Partial seizure			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastric perforation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Proctalgia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infections and infestations			
Device related sepsis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes virus infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Ridaforolimus 22 mg/m <sup>2</sup>	Ridaforolimus 33 mg/m <sup>2</sup>	Ridaforolimus 28mg/m <sup>2</sup>
Total subjects affected by non-serious adverse events subjects affected / exposed	4 / 4 (100.00%)	13 / 13 (100.00%)	3 / 3 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Vascular disorders Flushing subjects affected / exposed occurrences (all)  Hypertension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0  0 / 4 (0.00%) 0	1 / 13 (7.69%) 1  1 / 13 (7.69%) 1	0 / 3 (0.00%) 0  0 / 3 (0.00%) 0
General disorders and administration site conditions Catheter site pain subjects affected / exposed occurrences (all)  Chest pain subjects affected / exposed occurrences (all)  Chills subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)  Gait disturbance subjects affected / exposed occurrences (all)  Local swelling subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0  0 / 4 (0.00%) 0  1 / 4 (25.00%) 1  4 / 4 (100.00%) 4  0 / 4 (0.00%) 0  0 / 4 (0.00%) 0	1 / 13 (7.69%) 1  1 / 13 (7.69%) 1  1 / 13 (7.69%) 1  7 / 13 (53.85%) 8  1 / 13 (7.69%) 1  1 / 13 (7.69%) 1	0 / 3 (0.00%) 0  1 / 3 (33.33%) 2  0 / 3 (0.00%) 0  3 / 3 (100.00%) 3  0 / 3 (0.00%) 0  0 / 3 (0.00%) 0

Oedema peripheral subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	3 / 13 (23.08%) 3	0 / 3 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	3 / 4 (75.00%) 3	4 / 13 (30.77%) 4	1 / 3 (33.33%) 2
Thrombus in device subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Immune system disorders			
Seasonal allergy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	6 / 13 (46.15%) 8	1 / 3 (33.33%) 1
Dysphonia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	3 / 13 (23.08%) 3	1 / 3 (33.33%) 1
Epistaxis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	3 / 13 (23.08%) 3	0 / 3 (0.00%) 0
Haemoptysis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Hiccups subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Increased upper airway secretion			

subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Laryngeal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nasal dryness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	3 / 13 (23.08%)	0 / 3 (0.00%)
occurrences (all)	0	5	0
Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Respiratory distress			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Sputum discoloured			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	2 / 4 (50.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Anxiety			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	1	2	0
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Depression			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	9 / 13 (69.23%)	1 / 3 (33.33%)
occurrences (all)	4	15	1
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 4 (25.00%)	8 / 13 (61.54%)	2 / 3 (66.67%)
occurrences (all)	2	15	2
Blood albumin decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	1 / 3 (33.33%)
occurrences (all)	1	2	1
Blood bilirubin increased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	0 / 3 (0.00%)
occurrences (all)	1	5	0
Blood calcium decreased			
subjects affected / exposed	0 / 4 (0.00%)	3 / 13 (23.08%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
Blood chloride decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood cholesterol increased			
subjects affected / exposed	0 / 4 (0.00%)	5 / 13 (38.46%)	0 / 3 (0.00%)
occurrences (all)	0	8	0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood creatinine increased			

subjects affected / exposed	0 / 4 (0.00%)	6 / 13 (46.15%)	0 / 3 (0.00%)
occurrences (all)	0	6	0
Blood glucose decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood glucose increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Blood magnesium decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Blood magnesium increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Blood phosphorus decreased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	0 / 3 (0.00%)
occurrences (all)	1	8	0
Blood phosphorus increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood potassium decreased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 13 (7.69%)	1 / 3 (33.33%)
occurrences (all)	6	3	1
Blood selenium increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Blood sodium decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Blood triglycerides increased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	1 / 3 (33.33%)
occurrences (all)	2	5	2
C-reactive protein increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Gamma-glutamyltransferase			

increased			
subjects affected / exposed	1 / 4 (25.00%)	5 / 13 (38.46%)	2 / 3 (66.67%)
occurrences (all)	1	6	2
Haemoglobin decreased			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	1 / 3 (33.33%)
occurrences (all)	4	6	2
International normalised ratio decreased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	0 / 3 (0.00%)
occurrences (all)	5	5	0
Neutrophil count decreased			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	4	2	0
Platelet count decreased			
subjects affected / exposed	1 / 4 (25.00%)	10 / 13 (76.92%)	0 / 3 (0.00%)
occurrences (all)	3	17	0
Reticulocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	4 / 13 (30.77%)	0 / 3 (0.00%)
occurrences (all)	0	4	0
White blood cell count decreased			
subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	2 / 3 (66.67%)
occurrences (all)	5	9	3
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Animal bite			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Fall			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Procedural pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 2	0 / 3 (0.00%) 0
Cardiac disorders			
Tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Wolff-Parkinson-White syndrome subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Nervous system disorders			
Amnesia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1
Ataxia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1
Dysarthria subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1
Dysgeusia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	3 / 13 (23.08%) 3	0 / 3 (0.00%) 0
Extrapyramidal disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	3 / 4 (75.00%) 6	6 / 13 (46.15%) 11	1 / 3 (33.33%) 2
Hyporeflexia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1
Paraesthesia			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Paraparesis subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
V11th nerve paralysis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 2	0 / 3 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 2	3 / 13 (23.08%) 6	0 / 3 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0
Lymphopenia subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	0 / 13 (0.00%) 0	0 / 3 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 4	3 / 13 (23.08%) 6	1 / 3 (33.33%) 1
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 13 (0.00%) 0	1 / 3 (33.33%) 1
Ear and labyrinth disorders			
Ear pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Eye disorders			

Dry eye			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Eyelid ptosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Mydriasis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Photophobia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 13 (15.38%)	1 / 3 (33.33%)
occurrences (all)	0	2	1
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	2 / 4 (50.00%)	2 / 13 (15.38%)	1 / 3 (33.33%)
occurrences (all)	4	2	1
Aphthous stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	1 / 4 (25.00%)	6 / 13 (46.15%)	2 / 3 (66.67%)
occurrences (all)	1	7	2
Diarrhoea			
subjects affected / exposed	1 / 4 (25.00%)	6 / 13 (46.15%)	0 / 3 (0.00%)
occurrences (all)	2	11	0
Dry mouth			
subjects affected / exposed	2 / 4 (50.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	3	1	0
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Gastroesophageal reflux disease			

subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia oral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Lip dry			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Lip Pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	4 / 4 (100.00%)	8 / 13 (61.54%)	2 / 3 (66.67%)
occurrences (all)	6	11	2
Odynophagia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oral dysaesthesia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Salivary hypersecretion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Stomatitis			
subjects affected / exposed	2 / 4 (50.00%)	10 / 13 (76.92%)	3 / 3 (100.00%)
occurrences (all)	3	18	4
Toothache			
subjects affected / exposed	0 / 4 (0.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
Vomiting			
subjects affected / exposed	2 / 4 (50.00%)	7 / 13 (53.85%)	1 / 3 (33.33%)
occurrences (all)	12	10	1
Skin and subcutaneous tissue disorders			

Decubitus ulcer			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Eczema			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hair texture abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Petechiae			
subjects affected / exposed	0 / 4 (0.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	1 / 4 (25.00%)	1 / 13 (7.69%)	1 / 3 (33.33%)
occurrences (all)	1	1	1
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Skin lesion			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Skin striae			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Enuresis			

subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
<b>Haematuria</b>			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
<b>Haemorrhage urinary tract</b>			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
<b>Micturition urgency</b>			
subjects affected / exposed	0 / 4 (0.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
<b>Pollakiuria</b>			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
<b>Proteinuria</b>			
subjects affected / exposed	0 / 4 (0.00%)	3 / 13 (23.08%)	0 / 3 (0.00%)
occurrences (all)	0	3	0
<b>Urinary hesitation</b>			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
<b>Urinary incontinence</b>			
subjects affected / exposed	2 / 4 (50.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	2	1	0
<b>Endocrine disorders</b>			
<b>Cushingoid</b>			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Arthralgia</b>			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	3 / 3 (100.00%)
occurrences (all)	1	2	3
<b>Back pain</b>			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	1 / 3 (33.33%)
occurrences (all)	1	2	1
<b>Bone pain</b>			

subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	2 / 3 (66.67%)
occurrences (all)	0	0	2
Muscle spasms			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal pain			
subjects affected / exposed	2 / 4 (50.00%)	3 / 13 (23.08%)	2 / 3 (66.67%)
occurrences (all)	5	3	2
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Myopathy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 13 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	1 / 4 (25.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Osteonecrosis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	0 / 3 (0.00%)
occurrences (all)	4	6	0
Pain in jaw			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Infections and infestations			
Catheter site infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0

Ear infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Genital herpes			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Impetigo			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 4 (25.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	1	1	0
Oral herpes			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Otitis media			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pleural infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Rhinitis			
subjects affected / exposed	0 / 4 (0.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Skin infection			
subjects affected / exposed	1 / 4 (25.00%)	0 / 13 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Staphylococcal skin infection			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Tracheitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Varicella subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Vulvitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Wound infection subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	6 / 13 (46.15%) 7	2 / 3 (66.67%) 2
Dehydration subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Hypercholesterolemia subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 3	1 / 13 (7.69%) 1	1 / 3 (33.33%) 2
Fluid retention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 1	0 / 3 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	4 / 13 (30.77%) 7	0 / 3 (0.00%) 0
Hypernatraemia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 13 (7.69%) 2	0 / 3 (0.00%) 0
Hypertriglyceridaemia			

subjects affected / exposed	1 / 4 (25.00%)	4 / 13 (30.77%)	0 / 3 (0.00%)
occurrences (all)	1	4	0
Hypoalbuminaemia			
subjects affected / exposed	1 / 4 (25.00%)	2 / 13 (15.38%)	0 / 3 (0.00%)
occurrences (all)	1	4	0
Hypocalcaemia			
subjects affected / exposed	1 / 4 (25.00%)	3 / 13 (23.08%)	0 / 3 (0.00%)
occurrences (all)	1	6	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	1 / 4 (25.00%)	3 / 13 (23.08%)	0 / 3 (0.00%)
occurrences (all)	2	9	0
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	5	0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Hypophosphataemia			
subjects affected / exposed	2 / 4 (50.00%)	1 / 13 (7.69%)	1 / 3 (33.33%)
occurrences (all)	3	6	2
Iron deficiency			
subjects affected / exposed	0 / 4 (0.00%)	1 / 13 (7.69%)	0 / 3 (0.00%)
occurrences (all)	0	1	0

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported